AU
UK
CA
NZ
IND
US
Palisade Bio, Inc. (NASDAQ:PALI), a clinical-stage biopharmaceutical company developing therapies for autoimmune, inflammatory, and fibrotic diseases, announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application. The approval allows the company to advance PALI-2108, a first-in-class …
AC Immune SA (NASDAQ: ACIU) has announced a strategic restructuring aimed at streamlining operations and concentrating resources on its highest-value programs. The plan includes a 30% workforce reduction and a narrowed focus on three clinical-stage active immunotherapy programs, along with small molecule programs targeting …
Zai Lab Limited (NASDAQ: ZLAB) announced that Hong Kong’s Department of Health has approved TIVDAK (tisotumab vedotin-tftv), its antibody-drug conjugate (ADC) therapy for adult patients with recurrent or metastatic cervical cancer who experienced disease progression during or after chemotherapy. This marks an important regulatory …
Kiniksa Pharmaceuticals International (NASDAQ: KNSA) received a rating downgrade from Wall Street Zen, shifting from a “strong-buy” to a “buy” recommendation in a recent research note issued on Saturday. This adjustment reflects a slightly more cautious stance from analysts, although sentiment toward the stock …
Cantor Fitzgerald reaffirmed its “neutral” rating on shares of Molina Healthcare (NYSE: MOH - Get Free Report) in a research note issued Tuesday, according to Benzinga. The firm set a target price of USD 210.00, suggesting potential upside of just over 20% from the …
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has entered a strategic partnership with InvestorHub, a direct-to-investor engagement software provider, as part of a broader effort to streamline communications with shareholders and the investment community. The agreement establishes an interactive investor hub designed to consolidate corporate …
Evoke Pharma announced a set of distribution agreements intended to materially broaden patient access to GIMOTI® nasal spray, the only FDA-approved intranasal treatment for adults with acute and recurrent diabetic gastroparesis. The company said strategic arrangements with Omnicell (NASDAQ: OMCL) and Brentwood Pharmacy will …
Marker Therapeutics reported encouraging early efficacy and tolerability data from its Phase 1 APOLLO study of MT-601, a Multi-Antigen Recognizing T cell product, in relapsed lymphoma. The trial enrolled 24 B-cell lymphoma patients across seven U.S. clinical sites with dose levels spanning 100×10^6 to …
Serina Therapeutics (NYSE American: SER) said the U.S. Food and Drug Administration gave constructive feedback that supports advancing SER-252, a POZ-enabled apomorphine formulation aimed at treating advanced Parkinson’s disease, via a 505(b)(2) NDA pathway. The company plans to launch a registrational clinical development program …
Eisai Co., Ltd. and Biogen Inc. announced the first European launches of LEQEMBI® (lecanemab) in Austria on August 25, 2025, with Germany to follow on September 1, 2025 — the initial rollout following the European Commission’s marketing authorisation in April 2025. These are the …
Please wait processing your request...